| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ATLANTA – October 30, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and ... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- |
| 11 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This SECURITES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 7, 2026, by and among Femasys Inc., a Delaware corporation (the “Company”), and the entity listed on such Purchaser’s signature page attached to this Agreement (e... |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders of Femasys Inc. (the “Company”) was held on June 24, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 1,487,447 shares (post stock-spli... |
| 24 Jun 2026 |
8-K: Other Events
ATLANTA – June 24, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it re... |
| 05 Jun 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Femasys Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure
On June 4, 2026, Femasys Inc. (the “Company”) announced that it will effect a 1-for-20 reverse stock split of its common stock, par value $0.001 per share (the “Common Stock”), that will become effective at 4:30 p.m. Eastern Time on June... |
| 13 May 2026 |
8-K: Regulation FD Disclosure
CONFIDENTAIL | NASDAQ: FEMY 1 CORPORATE PRESENTATION May 2026 ©️ 2026 Femasys Inc. Redefining Women’s Reproductive Health at Global Scale NASDAQ: FEMY |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- |
| 29 Apr 2026 |
8-K: Submission of Matters to a Vote of Security Holders
A Special Meeting of Stockholders of Femasys Inc. (the “Company”) was held on April 29, 2026 (the “Special Meeting”). At the Special Meeting, there were present, in person virtually or by proxy, holders of 24,102,261 shares of common sto... |
| 01 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 30, 2026 by and between FEMASYS INC., a Delaware corporation (the “Company”), and JOHN CHARLES CANNING, an individual resident of the state of Florida (th... |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- |
| 20 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURIT... |
| 15 Jan 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 23 Dec 2025 |
8-K: Other Events
1095 Avenue of the Americas New York, NY 10036-6797 +1 212 698 3500 Main |
| 18 Dec 2025 |
8-K: Other Events
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – |
| 10 Nov 2025 |
8-K: Other Events
-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- |
| 07 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURIT... |
Loading...